138 related articles for article (PubMed ID: 36105450)
1. Evaluation of Short-Term Efficacy of PD-1 Monoclonal Antibody Immunotherapy for Lymphoma by Positron Emission Tomography/Computed Tomography Imaging with Convolutional Neural Network Image Registration Algorithm.
Fang J; Chen Z
Contrast Media Mol Imaging; 2022; 2022():1388517. PubMed ID: 36105450
[TBL] [Abstract][Full Text] [Related]
2. PET/CT Imaging of
Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
[TBL] [Abstract][Full Text] [Related]
3. [Application of anti-programmed cell death protein 1 antibody in children with refractory or relapsed Hodgkin lymphoma].
Li Y; Duan YL; Huang M; Zhang L; Jin YG; Zhang XL; Wang X
Zhonghua Er Ke Za Zhi; 2022 Jun; 60(6):573-577. PubMed ID: 35658365
[No Abstract] [Full Text] [Related]
4. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Freedman A; Neelapu SS; Nichols C; Robertson MJ; Djulbegovic B; Winter JN; Bender JF; Gold DP; Ghalie RG; Stewart ME; Esquibel V; Hamlin P
J Clin Oncol; 2009 Jun; 27(18):3036-43. PubMed ID: 19414675
[TBL] [Abstract][Full Text] [Related]
5. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
6. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
7. Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies.
Dercle L; Mokrane FZ; Schiano de Colella JM; Stamatoullas A; Morschhauser F; Brice P; Ghesquières H; Casasnovas O; Chen A; Manson G; Houot R
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1391-1392. PubMed ID: 30888476
[No Abstract] [Full Text] [Related]
8.
Sibille L; Seifert R; Avramovic N; Vehren T; Spottiswoode B; Zuehlsdorff S; Schäfers M
Radiology; 2020 Feb; 294(2):445-452. PubMed ID: 31821122
[TBL] [Abstract][Full Text] [Related]
9. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
10. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
11. Study of
Niemeijer AN; Oprea-Lager DE; Huisman MC; Hoekstra OS; Boellaard R; de Wit-van der Veen BJ; Bahce I; Vugts DJ; van Dongen GAMS; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 Mar; 63(3):362-367. PubMed ID: 34272316
[TBL] [Abstract][Full Text] [Related]
12. Deep Learning-Based CT Imaging in the Diagnosis of Treatment Effect of Pulmonary Nodules and Radiofrequency Ablation.
Zhou C; Zhao X; Zhao L; Liu J; Chen Z; Fang S
Comput Intell Neurosci; 2022; 2022():7326537. PubMed ID: 35996649
[TBL] [Abstract][Full Text] [Related]
13. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.
Melani C; Major A; Schowinsky J; Roschewski M; Pittaluga S; Jaffe ES; Pack SD; Abdullaev Z; Ahlman MA; Kwak JJ; Morgan R; Rabinovitch R; Pan Z; Haverkos BM; Gutman JA; Pollyea DA; Smith CA; Wilson WH; Kamdar M
N Engl J Med; 2017 Jul; 377(1):89-91. PubMed ID: 28679093
[No Abstract] [Full Text] [Related]
14. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation Value of Invasion Area PET-CT Scanning for Chemotherapeutic Efficacy and Prognosis of Patients with Lymphoma].
Wang J; Pang H; Jing XG; Duan D; Xu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):106-9. PubMed ID: 26913404
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
19. Early
Chen A; Mokrane FZ; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Dulery R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Armand P; Houot R; Dercle L
J Nucl Med; 2020 May; 61(5):649-654. PubMed ID: 31628220
[TBL] [Abstract][Full Text] [Related]
20. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Blanc-Durand P; Jégou S; Kanoun S; Berriolo-Riedinger A; Bodet-Milin C; Kraeber-Bodéré F; Carlier T; Le Gouill S; Casasnovas RO; Meignan M; Itti E
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1362-1370. PubMed ID: 33097974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
